Deenen MJ - Search Results

1

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH. Meulendijks D, et al. Among authors: deenen mj. Int J Cancer. 2016 Jun 1;138(11):2752-61. doi: 10.1002/ijc.30014. Epub 2016 Feb 19. Int J Cancer. 2016. PMID: 26804235

2

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.

Brandon EF, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JB, Bijl M, Beijnen JH, Schellens JH, Meijerman I. Brandon EF, et al. Among authors: deenen mj. Toxicol Appl Pharmacol. 2006 Feb 15;211(1):1-10. doi: 10.1016/j.taap.2005.05.004. Epub 2005 Jun 21. Toxicol Appl Pharmacol. 2006. PMID: 15975613

3

Screening for polymorphisms in the PXR gene in a Dutch population.

Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH, Meijerman I. Bosch TM, et al. Eur J Clin Pharmacol. 2006 May;62(5):395-9. doi: 10.1007/s00228-006-0108-0. Epub 2006 Mar 28. Eur J Clin Pharmacol. 2006. PMID: 16568343

4

Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?

Deenen MJ, Beijnen JH, Schellens JH. Deenen MJ, et al. J Clin Oncol. 2008 Oct 20;26(30):4997-8; author reply 4998-9. doi: 10.1200/JCO.2008.18.8565. Epub 2008 Sep 22. J Clin Oncol. 2008. PMID: 18809598 No abstract available.

5

Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

Deenen MJ, Terpstra WE, Cats A, Boot H, Schellens JH. Deenen MJ, et al. Ann Intern Med. 2010 Dec 7;153(11):767-8. doi: 10.7326/0003-4819-153-11-201012070-00023. Ann Intern Med. 2010. PMID: 21135311 No abstract available.

6

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Deenen MJ, et al. Clin Cancer Res. 2011 May 15;17(10):3455-68. doi: 10.1158/1078-0432.CCR-10-2209. Epub 2011 Apr 15. Clin Cancer Res. 2011. PMID: 21498394 Free article.

7

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(6):811-9. doi: 10.1634/theoncologist.2010-0258. Epub 2011 May 31. Oncologist. 2011. PMID: 21632456 Free PMC article. Review.

8

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(6):820-34. doi: 10.1634/theoncologist.2010-0259. Epub 2011 May 31. Oncologist. 2011. PMID: 21632461 Free PMC article. Review.

9

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(7):992-1005. doi: 10.1634/theoncologist.2010-0260. Epub 2011 Jun 9. Oncologist. 2011. PMID: 21659608 Free PMC article. Review.

10

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(7):1006-20. doi: 10.1634/theoncologist.2010-0261. Epub 2011 Jun 9. Oncologist. 2011. PMID: 21659612 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page